Mind Medicine Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation in Adults with Generalized Anxiety Disorder
Journal of the American Medical Association Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 in Generalized Anxiety Disorder
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
